Skip to main content
Erschienen in: Diagnostic Pathology 1/2011

Open Access 01.12.2011 | Research

Maspin and MCM2 immunoprofiling in salivary gland carcinomas

verfasst von: Shaimaa E Ghazy, Iman M Helmy, Houry M Baghdadi

Erschienen in: Diagnostic Pathology | Ausgabe 1/2011

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

The pathogenesis of salivary gland carcinomas is very complex and prognostic markers are difficult to find in these carcinomas of which the different subtypes have varying malignant potential. The study was conducted to examine the cellular distribution of maspin and MCM2 in salivary gland carcinomas and their value to predict lymph node metastasis.

Materials and methods

Fifty three paraffin blocks of different lesions (15 muco-epidermoid carcinoma, 14 adenoid cystic carcinoma, 3 epi-myoepithelial carcinoma, 5 salivary duct carcinoma, 5 malignant pleomorphic adenoma, 6 polymorphous low grade adenocarcinoma and 5 acinic cell carcinoma) were prepared for immunohistochemical staining with maspin and MCM2 antibodies. ANOVA and Pearson correlation tests were used for the statistical analysis of the results.

Results

All salivary gland carcinomas express maspin and MCM2 with variable cellular localization. There was a significant difference in the expression of each antibody between mucoepidermoid carcinoma, adenoid cystic carcinoma and polymorphous low grade adenocarcinoma. No association was found between examined markers and lymph node metastasis.

Conclusions

Salivary gland carcinomas express maspin and MCM2 with variable levels and cellular localization, consisting important markers of biological behavior in these tumors. The level of MCM2 expression can be used in the differential diagnosis of adenoid cystic carcinoma and polymorphous low grade adenocarcinoma. Further study with large sample size is recommended to assess their value in prediction of lymph node metastasis.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1746-1596-6-89) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SE participated in collection of data and references, immunohistochemical staining and evaluation by image analysis. IH participated in the design of the study, performed the statistical analysis and drafted the manuscript. HB participated in the design and coordination, sequence alignment and reviewing the manuscript. All authors read and approved the final manuscript.

Introduction

Salivary gland neoplasms which comprise about 5% of head and neck cancers are a morphologically and clinically diverse group of lesions and may present considerable diagnostic challenge to the pathologist [1]. The most frequent salivary gland carcinoma types are mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma, malignant pleomorphic adenoma and salivary duct carcinoma [2].
Mammary Serine Protease Inhibitor (maspin) belongs to the serine protease inhibitor (serpin) family [3, 4], which comprises a large protein family with diverse biological functions [5]. There is a controversy about maspin protease inhibition; Sheng et al [6] stated that maspin has protease inhibitory activity. On the contrary, Bass et al [7] reported that maspin has no protease inhibitory properties.
Maspin expression has been demonstrated in multiple tissues including epithelium of the breast, prostate, lung and in stromal cells of the cornea [810]. Maspin demonstrates broad localization patterns [5], in mammary epithelial cells, maspin localizes primarily to the cytoplasm, but can also localize to the nucleus, and the cell surface [11].
One of the first regulatory mechanisms identified for maspin involved p53 signaling. The regulation of maspin by p53 could explain the role of p53 in cell invasion and metastasis and hypothesizes that cancer cells expressing mutant p53 would be more likely to metastasize, in part due to the inability to upregulate the maspin gene [5]. In addition, increased maspin was associated with an increase in apoptosis and a reduction in cell invasion. This effect was blocked by the addition of a maspin-blocking antibody [12].
Recent study has also established a role for the common breast cancer drug Tamoxifen (TAM) in regulating the expression of maspin [5]. The clinical efficacy of TAM has been attributed to growth arrest and induction of apoptosis in breast cancer cells. TAM was shown to induce maspin expression in vitro and in situ [13]. Also, it was suggested that maspin has an inhibitory effect on tumor induced angiogenesis [14], cell motility, invasion and metastasis [15]. Extensive studies have been undertaken to determine the mechanisms employed by maspin to produce its anti-metastatic effects. One line of evidence suggests that maspin regulates cell invasion by altering the integrin profile of the cell [5]. In support of a cell surface event, it has been reported that cell surface-associated maspin is primarily responsible for its anti-invasive properties [16].
Several reports indicated that maspin can function as an inhibitor of angiogenesis. Both rMaspin and secreted maspin can impede the migration of cultured endothelial cells toward bFGF and VEGF which act as important chemo-attractants during angiogenesis. Also, maspin was shown to effectively block neovascularization and reduce the density of the neoplasm-associated microvessels in vivo [17, 18]. Solomon et al [19] reported that neoplasms with both cytoplasmic and nuclear maspin expression had lower VEGF and cyclooxygenase-2 (COX-2) expression than neoplasms with cytoplasmic maspin expression only, so suppression of VEGF by maspin may thus occur through a COX-2 mediated pathway.
In addition to its anti-angiogenic properties, maspin has also been implicated in apoptosis [5]. It has been demonstrated that maspin sensitizes breast cancer cells to staurosporine (STS)-induced apoptosis [20]. Staurosporine is a synthetic chemical known to induce apoptosis via an intrinsic pathway [21]. The apoptotic effect of maspin appears to be tumor-specific since normal epithelial cells that express maspin at a high level are not sensitized to drug-induced apoptosis [22].
The ubiquitous localization of maspin (cytoplasmic, nuclear, cell surface-associated, secreted) suggests that maspin may be involved in multiple pathways and processes. Loss of maspin has been associated with poor prognosis in various malignant neoplasms like ovarian cancer, oral squamous cell carcinoma, lung and prostate cancer [2325].
The MCM (minichromosome maintance) proteins identify a group of ten conserved factors functioning in the replication of the genome of eukaryotic organisms [26]. Among these, MCM2-7 proteins are related to each other and form a complex implicated at the initiation step of DNA synthesis. MCM2-7 act as licensing factors for DNA replication to ensure that the genome is replicated only once in each cell cycle [26, 27].
Since MCM activity is essential for DNA replication in dividing cells and is lost in quiescence [28], MCMs are obvious markers for proliferation [26]. Molecular studies suggested that increased levels of MCMs mark not only proliferative malignant cells, but also precancerous cells and the potential for recurrence [29, 30]. In breast cancers, increasing neoplasm grade is associated with increased MCM2 expression [31]. Thus, they may prove to be effective markers for diagnosis of neoplasms [26].
Several studies reported that MCM2 and Ki-67 are both markers of cellular proliferation and required for cell cycle progression [32]. They showed that anti-MCM2 antibody stained a larger number of cells than anti Ki-67, suggesting that Ki-67 may be expressed during a shorter interval of the cell cycle than MCM2 [33]. MCM2 is present throughout the four phases of cell cycle [31], while Ki-67 is predominantly expressed during S, G2 and M phases. The present study aimed to evaluate the expression of maspin and MCM2 in salivary gland carcinomas and their value to predict lymph node metastasis.

Materials and methods

The material of this study consisted of 53 formalin-fixed, paraffin-embedded specimens of malignant salivary gland neoplasms, all collected from the archives of the General Pathology Department, Faculty of Medicine, Ain Shams University and National Cancer Institute, Cairo University. Fifteen cases of mucoepidermoid carcinoma (MEC), 10 of which were diagnosed as high grade and the other 5 cases as low grade, 14 cases of adenoid cystic carcinoma (ADCC), 5 cases of salivary duct carcinoma (SDC), 3 cases of epi-myoepithelial carcinoma (EMC), 5 cases of malignant pleomorphic adenoma (MPA), 6 cases of polymorphous low-grade adenocarcinoma (PLGA) and 5 cases of acinic cell carcinoma (ACC). Clinical information about lymph node metastasis was obtained from patients' medical records (summary of cases is displayed in table 1). For all specimens five micrometer thick sections were prepared and stained with hematoxylin and eosin to confirm the diagnosis.
Table 1
Types of cases and association with lymph node metastasis of the selected cases.
Malignant Salivary
Gland Neoplasms
Total Number of cases
Number of cases
Associated with lymph node
metastasis
MEC
15
4 (high grade variant)
ADCC
14
4 (2 of solid type and 2 of cribriform type)
EMC
3
-
SDC
5
2
M PA
5
-
PLGA
6
-
ACC
5
1
Total
53
11
In summary, immunohistochemical staining is performed as follows: the tissues were deparaffinized in xylene and hydrated through graded alcohol and washed with tap water. Based on the manufacturers' recommendation, the slides were transferred for antigen retrieval. The slides were washed with phosphate buffer and separately incubated with maspin (Visionbiosystems Novocastra™ Laboratories, Ltd, United Kingdom) diluted at a ratio of 1:30 and MCM2 (Lab Vision Corporation, USA) diluted at a ratio of 1:50 over-night. The slides were then washed again in PBS and incubated with biotinylated antibody for 30 minutes, and then were washed in PBS. Finally, the slides were incubated with peroxidase labeled streptavidin for 30 minutes and washed in PBS. Subsequently, DAB chromogen was applied for antibody staining (brown). The samples were then allowed to react with Mayer's hematoxylin for 5 minutes, dehydrated and covered with cover glass.
For each positive section, 6 microscopic fields showing highest immunopositivity were selected and photomicrographs were captured at original magnification 40×. This was performed using a digital camera (C5060, Olympus, Japan) mounted by a C-mount to a light microscope (BX60, Olympus, Japan). All the steps for immunohistochemical evaluation were carried out using image analysis software (Image J, 1.41a, NIH, USA). The area fraction (AF) of the positive cells was calculated automatically. The area fraction represented the percentage of immunopositive area to the total area of the microscopic field. The collected data was tabulated in an excel sheet and statistically analyzed using SPSS 15.

Results

All cases of MEC demonstrated maspin immunoreactivity. Most of the epidermoid cells in the cases diagnosed as high grade were negative for maspin, with a few positive cells in which the reaction was cytoplasmic. The mucous-secreting cells showed membranous staining. Low grade MEC showed more positive cells with nuclear and cytoplasmic staining of the epidermoid cells (Figure 1a). Concerning MCM2, most of the epidermoid cells revealed cytoplasmic staining in high grade cases (Figure 2a), while in low grade cases, little number of epidermoid cells were positive.
In ADCC, 12 cases of cribriform pattern demonstrated cytoplasmic maspin and MCM2 staining (Figure 1b, 2b). Two cases of solid pattern were negative for maspin but revealed cytoplasmic reaction for MCM2. Myoepithelial cells were negative for both antibodies.
In EMC, the neoplastic cells demonstrated cytoplasmic and nuclear (either the whole nucleus or confined only to the nuclear membrane) maspin staining and cytoplasmic MCM2 staining (Figure 1c, 2c). Few neoplastic cells were negative for maspin and MCM2.
In SDC, cases with solid and papillary pattern showed cytoplasmic maspin and MCM2 reaction (Figure 1d, 2d). In cribriform pattern with comedo necrosis, little nuclear and mainly cytoplasmic maspin reaction was detected, while MCM2 revealed cytoplasmic reaction only.
In MPA, all cases revealed nuclear and cytoplasmic maspin and MCM2 reaction in epithelial and some myoepithelial cells (Figure 1e, 2e), but in PLGA, there was cytoplasmic reaction for both antibodies in neoplastic cells arranged in cribriform and cystic pattern (Figure 1f, 2f). In ACC, one case of clear cell variant demonstrated membranous maspin and MCM2 reaction, while the remaining cases showed nuclear and cytoplasmic reaction for both antibodies (Figure 1g, 2g).
Statistically, ANOVA test revealed significant difference in the expression of both markers between MEC, ADCC and PLGA (P value = 0.000) (table 2, 3). Results of Post Hoc test for maspin and MCM2 expression are shown in table 4 and 5 respectively. Pearson's correlation analysis revealed no significant correlation between both maspin or MCM2 expression and lymph node metastasis.
Table 2
ANOVA for maspin
ANOVA
MEAN AF
 
Sum of Squares
df
Mean Square
F
Sig.
Between Groups
3682.051
2
1841.026
683.744
.000
Within Groups
80.777
30
2.693
  
Total
3762.828
32
   
Table 3
ANOVA for MCM2
ANOVA
MEAN AF
 
Sum of Squares
df
Mean Square
F
Sig.
Between Groups
713.006
2
356.503
39.753
.000
Within Groups
286.978
32
8.968
  
Total
999.984
34
   
Table 4
Post Hoc Test for maspin
Multiple Comparisons
MEAN AF
Tukey HSD
(I) type of lesion
(J) type of lesion
Mean Difference (I-J)
Std. Error
Sig.
95% Confidence Interval
     
Lower Bound
Upper Bound
MEC
adcc
-9.40967*
.63552
.000
-10.9764
-7.8429
 
Poly LG AdenoCa
-29.27800*
.79263
.000
-31.2321
-27.3239
adcc
MEC
9.40967*
.63552
.000
7.8429
10.9764
 
Poly LG AdenoCa
-19.86833*
.82045
.000
-21.8910
-17.8457
Poly LG AdenoCa
MEC
29.27800*
.79263
.000
27.3239
31.2321
 
adcc
19.86833*
.82045
.000
17.8457
21.8910
*. The mean difference is significant at the 0.05 level.
Table 5
Post Hoc Test for MCM2
Multiple Comparisons
MEAN AF
Tukey HSD
(I) type of lesion
(J) type of lesion
Mean Difference (I-J)
Std. Error
Sig.
95% Confidence Interval
     
Lower Bound
Upper Bound
MEC
adcc
-2.52957
1.11285
.074
-5.2643
.2051
 
Poly LG AdenoCa
10.35900*
1.44656
.000
6.8043
13.9137
adcc
MEC
2.52957
1.11285
.074
-.2051
5.2643
 
Poly LG AdenoCa
12.88857*
1.46125
.000
9.2977
16.4794
Poly LG AdenoCa
MEC
-10.35900*
1.44656
.000
-13.9137
-6.8043
 
adcc
-12.88857*
1.46125
.000
-16.4794
-9.2977
*. The mean difference is significant at the 0.05 level.

Discussion

Salivary gland neoplasms are a relatively rare and morphologically diverse group of lesions. A diagnosis based on hematoxylin and eosin stained sections remains the gold standard in salivary gland pathology [1].
Several studies were performed to detect the expression of maspin protein in different malignant neoplasms such as ovarian carcinoma, oral squamous cell carcinoma, pulmonary adenocarcinoma and prostate carcinoma to clarify its role in malignancy. Most researchers found that the increased maspin expression does correlate with better prognosis in these neoplasms [19, 2325].
Recent studies have proposed that MCM proteins may be sensitive proliferation markers and may serve as novel biomarkers for prognostication and diagnosis of various premalignant and malignant lesions [31, 34, 35]. The superior sensitivity of the MCM proteins over the standard proliferation markers such as Ki-67 resides in the fact that MCMs identify not only cycling cells, but also non-cycling cells with proliferative potential [35].
High grade MEC is characterized by decreased maspin expression. Loss or decreased expression of maspin indicates loss of its role in inhibition of tumor invasion, metastasis and angiogenesis [3]. Evidence of both nuclear and cytoplasmic maspin expression was observed in low grade MEC; this finding denotes that maspin cellular localization has an influence on its role as tumor suppressor gene [5]. Sood et al [36] demonstrated that mixed nuclear and cytoplasmic maspin localization in ovarian cancer is indicative of a more benign lesion than neoplasms with cytoplasmic expression only, suggesting an important tumor-suppressive role for nuclear maspin. This maspin nuclear localization pattern had been seen in other neoplasms as well, including non-small cell lung carcinoma and pancreatic cancer, where predominantly nuclear maspin is associated with favorable morphologic features [11, 24].
The high grade MEC cases showed a marked increase of MCM2 expression when compared to the low grade cases, which was also in agreement with Vargas et al [34]. This might be explained by the fact that in cancer, differentiated neoplastic cells tend to grow and spread at a slower rate than undifferentiated or poorly differentiated cells, which lack the structure and function of normal cells and grow uncontrollably [37]. It was stated that withdrawal of cells from the cell cycle into differentiated state is coupled with downregulation of MCM2 expression [31, 35].
In ADCC, cases with solid pattern were maspin immunonegative, which was in agreement with Navarro et al [15] and indicates the aggressive behavior of this pattern. Maass et al [38] stated that maspin is lost in the metastatic cells, and Shwarz et al [3] reported in his study that in intermediate grade tumours (ADCC, MEC, carcinoma expleomorphic adenoma) loss of maspin expression, mainly localized to the nucleus, was associated with lymph node metastases.
Myoepithelial cells in ADCC were maspin immunonegative. This result was in agreement with Navarro et al [15]. Normally maspin is expressed in high amounts in myoepithelial cells and it was suggested that maspin can be used as a myoepithelial cell marker [39]. Thus, loss of maspin in this cell might indicate the role of myoepithelial cells in malignant transformation and histogenesis of this neoplasm [40].
Adenoid cystic carcinoma demonstrated high value of MCM2 expression; this finding gives an impression of the high proliferative power of ADCC. This result was consistent with previous study denoting that ADCC is a highly proliferative salivary gland neoplasm [34].
Myoepithelial carcinoma showed the smallest value of maspin expression, and high value of MCM2 expression. These values might indicate the aggressive behavior of this neoplasm. The knowledge of myoepithelial carcinoma behavior and the optimal line of management are deficient, possibly due to its rare occurrence and the lack of comprehensive reports of large case series [41]. However, some authors describe myoepithelial carcinoma by infiltrative growth and potential metastasis [2, 41, 42].
Salivary duct carcinoma revealed the highest value of MCM2 expression and reduced maspin expression; this finding confirms the high grade behavior of this tumor [43].
Malignant pleomorphic adenoma possessed the highest value of maspin expression and low MCM2 expression, this is in accordance with Umekita et al [44] who observed that high maspin expression in breast carcinoma was associated with poor prognosis, and this was explained by genetic alteration at the maspin gene locus contributing to the loss of tumor suppressing function of the maspin protein. Values of maspin and MCM2 expression in PLGA and ACC reflected low grade nature of these tumors which are characterized by a low metastatic potential and a high survival rate [2].
The differential diagnosis of both ADCC and PLGA is of a great interest as both share common histopathological features and may cause diagnostic difficulty particularly in small biopsies [1]. Our data demonstrated that ADCC has a higher proliferation power compared to PLGA as determined by MCM2 immunostaining. This result was in conformity with Vargas et al [34] who support the idea that proliferation markers can be used to differentiate borderline cases.
No significant correlation between maspin expression and lymph node metastasis was found in this study. This finding disagrees with Schwarz et al [3] who reported that lack of maspin expression was significantly correlated with positive lymph node metastasis. This might be due to the small sample size used in this study in which only 11 cases were associated with positive lymph node metastasis.
Also, there was no significant correlation between MCM2 expression and positive lymph node metastasis. This result was in agreement with Vargas et al [34] and was dissimilar to Guzinska-Ustymowiczi et al study [45] in which MCM2 over expression was associated with lymph node metastasis.
Maspin and MCM2 are important markers of biological behavior in salivary gland carcinomas. Further study with large sample size is required to clarify the correlation between maspin and MCM2 expression and lymph node metastasis.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SE participated in collection of data and references, immunohistochemical staining and evaluation by image analysis. IH participated in the design of the study, performed the statistical analysis and drafted the manuscript. HB participated in the design and coordination, sequence alignment and reviewing the manuscript. All authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Speight P, Barrett A: Salivary gland tumors. Oral Dis. 2002, 8: 229-240. 10.1034/j.1601-0825.2002.02870.x.CrossRefPubMed Speight P, Barrett A: Salivary gland tumors. Oral Dis. 2002, 8: 229-240. 10.1034/j.1601-0825.2002.02870.x.CrossRefPubMed
2.
Zurück zum Zitat Barnes L, Eveson J, Reichart P, Sidransky D: Salivary glands. Pathology and genetics of head and neck tumors. Edited by: Barnes L. 2005, Lyon: IARC Press, 212-213. Barnes L, Eveson J, Reichart P, Sidransky D: Salivary glands. Pathology and genetics of head and neck tumors. Edited by: Barnes L. 2005, Lyon: IARC Press, 212-213.
3.
Zurück zum Zitat Schwarz S, Ettl T, Kleinsasser K, Hartmann A, Reichert T, Driemel O: Loss of maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol. 2008, 44: 563-570. 10.1016/j.oraloncology.2007.07.004.CrossRefPubMed Schwarz S, Ettl T, Kleinsasser K, Hartmann A, Reichert T, Driemel O: Loss of maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol. 2008, 44: 563-570. 10.1016/j.oraloncology.2007.07.004.CrossRefPubMed
4.
Zurück zum Zitat Xia W, Lau Y, Hu M, Li L, Johnston D, Sheng S, El-Naggar A, Hung M: High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene. 2000, 19: 2398-2403. 10.1038/sj.onc.1203535.CrossRefPubMed Xia W, Lau Y, Hu M, Li L, Johnston D, Sheng S, El-Naggar A, Hung M: High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene. 2000, 19: 2398-2403. 10.1038/sj.onc.1203535.CrossRefPubMed
5.
Zurück zum Zitat Bailey C, Khalkhali-Ellis Z, Seftor E, Hendrix M: Biological functions of maspin. J Cell Physi. 2006, 209: 617-624. 10.1002/jcp.20782.CrossRef Bailey C, Khalkhali-Ellis Z, Seftor E, Hendrix M: Biological functions of maspin. J Cell Physi. 2006, 209: 617-624. 10.1002/jcp.20782.CrossRef
6.
Zurück zum Zitat Sheng S, Truong B, Fredrickson D, Wu R, Pardee A, Sager R: Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci. 1998, 95: 499-504. 10.1073/pnas.95.2.499.PubMedCentralCrossRefPubMed Sheng S, Truong B, Fredrickson D, Wu R, Pardee A, Sager R: Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci. 1998, 95: 499-504. 10.1073/pnas.95.2.499.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Bass R, Fernandez A, Ellis V: Maspin inhibits cell migration in the absence of protease inhibitory activity. J Biol Chem. 2002, 277: 46845-46848. 10.1074/jbc.C200532200.CrossRefPubMed Bass R, Fernandez A, Ellis V: Maspin inhibits cell migration in the absence of protease inhibitory activity. J Biol Chem. 2002, 277: 46845-46848. 10.1074/jbc.C200532200.CrossRefPubMed
8.
Zurück zum Zitat Ngamkitidechakul C, Burke J, O'Brien W, Twining S: Maspin: synthesis by human cornea and regulation of in vitro stromal cell adhesion to extracellular matrix. Invest Ophthalmol Vis Sci. 2001, 42: 3135-3141.PubMed Ngamkitidechakul C, Burke J, O'Brien W, Twining S: Maspin: synthesis by human cornea and regulation of in vitro stromal cell adhesion to extracellular matrix. Invest Ophthalmol Vis Sci. 2001, 42: 3135-3141.PubMed
9.
Zurück zum Zitat Reis-Filho J, Torio B, Albergaria A, Schmitt F: Maspin expression in normal skin and usual cutaneous carcinomas. Virchows Arch. 2002, 441: 551-558. 10.1007/s00428-002-0710-1.CrossRefPubMed Reis-Filho J, Torio B, Albergaria A, Schmitt F: Maspin expression in normal skin and usual cutaneous carcinomas. Virchows Arch. 2002, 441: 551-558. 10.1007/s00428-002-0710-1.CrossRefPubMed
10.
Zurück zum Zitat Yatabe Y, Mitsudomi T, Takahashi T: Maspin expression in normal lung and non-small cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene. 2004, 23: 4041-4049. 10.1038/sj.onc.1207557.CrossRefPubMed Yatabe Y, Mitsudomi T, Takahashi T: Maspin expression in normal lung and non-small cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene. 2004, 23: 4041-4049. 10.1038/sj.onc.1207557.CrossRefPubMed
11.
Zurück zum Zitat Nicolai M, Martin Z, Koichi N, Pierre R: Maspin locates to the nucleus in certain cell types. J Pathol. 2002, 197: 274-275. 10.1002/path.1103.CrossRef Nicolai M, Martin Z, Koichi N, Pierre R: Maspin locates to the nucleus in certain cell types. J Pathol. 2002, 197: 274-275. 10.1002/path.1103.CrossRef
12.
Zurück zum Zitat Khalkhali-Ellis Z, Hendrix M: Nitric oxide regulation of maspin expression in normal mammary epithelial and breast cancer cells. Am J Pathol. 2003, 162: 1411-1417. 10.1016/S0002-9440(10)64274-5.PubMedCentralCrossRefPubMed Khalkhali-Ellis Z, Hendrix M: Nitric oxide regulation of maspin expression in normal mammary epithelial and breast cancer cells. Am J Pathol. 2003, 162: 1411-1417. 10.1016/S0002-9440(10)64274-5.PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Mandlekar S, Kong A: Mechanism of tamoxifen induced apoptosis. Apoptosis. 2001, 6: 469-477. 10.1023/A:1012437607881.CrossRefPubMed Mandlekar S, Kong A: Mechanism of tamoxifen induced apoptosis. Apoptosis. 2001, 6: 469-477. 10.1023/A:1012437607881.CrossRefPubMed
14.
Zurück zum Zitat Cher M, Biliran H, Bhagat S, Meng Y, Che M, Lockett J, Abrams J, Fridman R, Zachareas M, Sheng S: Maspin expression inhibits osteolysis, tumor growth and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci. 2003, 100: 7847-7852. 10.1073/pnas.1331360100.PubMedCentralCrossRefPubMed Cher M, Biliran H, Bhagat S, Meng Y, Che M, Lockett J, Abrams J, Fridman R, Zachareas M, Sheng S: Maspin expression inhibits osteolysis, tumor growth and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci. 2003, 100: 7847-7852. 10.1073/pnas.1331360100.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Navarro R, Martins M, de Arau' jo V: Maspin expression in normal and neoplastic salivary gland. J Oral Pathol Med. 2004, 33: 435-440. 10.1111/j.1600-0714.2004.00220.x.CrossRef Navarro R, Martins M, de Arau' jo V: Maspin expression in normal and neoplastic salivary gland. J Oral Pathol Med. 2004, 33: 435-440. 10.1111/j.1600-0714.2004.00220.x.CrossRef
16.
Zurück zum Zitat Sheng S, Carey J, Seftor E, Dias L, Hendrix M, Sager R: Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci. 1996, 93: 11669-11674. 10.1073/pnas.93.21.11669.PubMedCentralCrossRefPubMed Sheng S, Carey J, Seftor E, Dias L, Hendrix M, Sager R: Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci. 1996, 93: 11669-11674. 10.1073/pnas.93.21.11669.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Nickoloff B, Lingen M, Chang B, Shen M, Swift M, Curry J, Bacon P, Bodner B, Roninson I: Tumor suppressor maspin is up-regulated during keratinocyte senescence, exerting a paracrine antiangiogenic activity. Cancer Res. 2004, 64: 2956-2961. 10.1158/0008-5472.CAN-03-2388.CrossRefPubMed Nickoloff B, Lingen M, Chang B, Shen M, Swift M, Curry J, Bacon P, Bodner B, Roninson I: Tumor suppressor maspin is up-regulated during keratinocyte senescence, exerting a paracrine antiangiogenic activity. Cancer Res. 2004, 64: 2956-2961. 10.1158/0008-5472.CAN-03-2388.CrossRefPubMed
18.
Zurück zum Zitat Zhang M, Volpert O, Shi Y, Bouck N: Maspin is an angiogenesis inhibitor. Nat Med. 2000, 6: 196-199. 10.1038/72303.CrossRefPubMed Zhang M, Volpert O, Shi Y, Bouck N: Maspin is an angiogenesis inhibitor. Nat Med. 2000, 6: 196-199. 10.1038/72303.CrossRefPubMed
19.
Zurück zum Zitat Solomon L, Munkarah A, Schimp V, Arabi M, Morris R, Nassar H, Ali-Fehmi R: Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol. 2006, 101: 385-389. 10.1016/j.ygyno.2005.11.049.CrossRefPubMed Solomon L, Munkarah A, Schimp V, Arabi M, Morris R, Nassar H, Ali-Fehmi R: Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol. 2006, 101: 385-389. 10.1016/j.ygyno.2005.11.049.CrossRefPubMed
20.
Zurück zum Zitat Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S: Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene. 2002, 21: 4089-4098. 10.1038/sj.onc.1205507.CrossRefPubMed Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S: Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene. 2002, 21: 4089-4098. 10.1038/sj.onc.1205507.CrossRefPubMed
21.
Zurück zum Zitat Duan S, Hajek P, Lin C, Shin S, Attardi G, Chomyn A: Mitochondrial outer membrane permeability change and hypersensitivity to digitonin early in staurosporine-induced apoptosis. J Biol Chem. 2003, 278: 1346-1353. 10.1074/jbc.M209269200.CrossRefPubMed Duan S, Hajek P, Lin C, Shin S, Attardi G, Chomyn A: Mitochondrial outer membrane permeability change and hypersensitivity to digitonin early in staurosporine-induced apoptosis. J Biol Chem. 2003, 278: 1346-1353. 10.1074/jbc.M209269200.CrossRefPubMed
22.
Zurück zum Zitat Sheng S: A role of novel serpin maspin in tumor progression: the divergence revealed through efforts to converge. J Cell Physi. 2006, 209: 631-635. 10.1002/jcp.20786.CrossRef Sheng S: A role of novel serpin maspin in tumor progression: the divergence revealed through efforts to converge. J Cell Physi. 2006, 209: 631-635. 10.1002/jcp.20786.CrossRef
23.
Zurück zum Zitat Yasumatsu R, Nakashima T, Hirakawa N, Kumamoto Y, Kuratomi K, Tomita K, Komiyama S: Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head Neck. 2001, 23: 962-966. 10.1002/hed.1139.CrossRefPubMed Yasumatsu R, Nakashima T, Hirakawa N, Kumamoto Y, Kuratomi K, Tomita K, Komiyama S: Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head Neck. 2001, 23: 962-966. 10.1002/hed.1139.CrossRefPubMed
24.
Zurück zum Zitat Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass H, Sheng S: Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer. 2006, 51: 31-39. 10.1016/j.lungcan.2005.07.011.CrossRefPubMed Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass H, Sheng S: Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer. 2006, 51: 31-39. 10.1016/j.lungcan.2005.07.011.CrossRefPubMed
25.
Zurück zum Zitat Stefan M, Jürgen S, Carsten B, Wolfgang B, Antje M, Christian K, Jörg H, Ruth K, Masahiko K, Udo J, Markus K: Expression of the p53 and maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer. 2001, 95: 337-342. 10.1002/1097-0215(20010920)95:5<337::AID-IJC1059>3.0.CO;2-1.CrossRef Stefan M, Jürgen S, Carsten B, Wolfgang B, Antje M, Christian K, Jörg H, Ruth K, Masahiko K, Udo J, Markus K: Expression of the p53 and maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer. 2001, 95: 337-342. 10.1002/1097-0215(20010920)95:5<337::AID-IJC1059>3.0.CO;2-1.CrossRef
26.
27.
Zurück zum Zitat Blow J, Dutta A: Preventing re-replication of chromosomal DNA. Nat Rev Mol Biol. 2005, 6: 476-486. 10.1038/nrm1663.CrossRef Blow J, Dutta A: Preventing re-replication of chromosomal DNA. Nat Rev Mol Biol. 2005, 6: 476-486. 10.1038/nrm1663.CrossRef
28.
Zurück zum Zitat Madine M, Swietlik M, Pelizon C, Romanowski P, Mills A, Laskey R: The roles of the MCM, ORC and Cdc6 proteins in determining the replication competence of chromatin in quiescent cells. J Struct Biol. 2000, 129: 198-210. 10.1006/jsbi.2000.4218.CrossRefPubMed Madine M, Swietlik M, Pelizon C, Romanowski P, Mills A, Laskey R: The roles of the MCM, ORC and Cdc6 proteins in determining the replication competence of chromatin in quiescent cells. J Struct Biol. 2000, 129: 198-210. 10.1006/jsbi.2000.4218.CrossRefPubMed
29.
Zurück zum Zitat Going J, Keith W, Neilson L, Stoeber K, Stuart R, Williams G: Aberrant expression of minichromosome maintenance proteins 2 and 5 and Ki-67 in dysplastic squamous esophageal epithelium and Barrett's mucosa. Gut. 2002, 50: 373-377. 10.1136/gut.50.3.373.PubMedCentralCrossRefPubMed Going J, Keith W, Neilson L, Stoeber K, Stuart R, Williams G: Aberrant expression of minichromosome maintenance proteins 2 and 5 and Ki-67 in dysplastic squamous esophageal epithelium and Barrett's mucosa. Gut. 2002, 50: 373-377. 10.1136/gut.50.3.373.PubMedCentralCrossRefPubMed
30.
31.
Zurück zum Zitat Fanshawe T, Prevost A, Sainsbury R, Williams G, Stoeber K: DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Brit J Cancer. 2005, 93: 1295-1300. 10.1038/sj.bjc.6602829.PubMedCentralCrossRefPubMed Fanshawe T, Prevost A, Sainsbury R, Williams G, Stoeber K: DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Brit J Cancer. 2005, 93: 1295-1300. 10.1038/sj.bjc.6602829.PubMedCentralCrossRefPubMed
32.
Zurück zum Zitat Lei M, Tye B: Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Sci. 2001, 14: 1447-1454. Lei M, Tye B: Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Sci. 2001, 14: 1447-1454.
33.
Zurück zum Zitat Tan D, Huberman J, Hyland A, Loewen G, Brooks J, Beck A, Todorov I, Bepler G: MCM2 a promising marker for premalignant lesions of the lung: a cohort study. BMC Cancer. 2001, 1: 1-6. 10.1186/1471-2407-1-1.CrossRef Tan D, Huberman J, Hyland A, Loewen G, Brooks J, Beck A, Todorov I, Bepler G: MCM2 a promising marker for premalignant lesions of the lung: a cohort study. BMC Cancer. 2001, 1: 1-6. 10.1186/1471-2407-1-1.CrossRef
34.
Zurück zum Zitat Vargas P, Cheng W, Barrett A, Craig G, Speight P: Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumors. J Oral Pathol Med. 2008, 37: 309-318. 10.1111/j.1600-0714.2007.00631.x.CrossRefPubMed Vargas P, Cheng W, Barrett A, Craig G, Speight P: Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumors. J Oral Pathol Med. 2008, 37: 309-318. 10.1111/j.1600-0714.2007.00631.x.CrossRefPubMed
35.
Zurück zum Zitat Stoeber K, Tlsty T, Happerfield L, Thomas G, Romanov S, Bobrow L, Williams E, Williams G: DNA replication, licensing and human cell proliferation. J Cell Sci. 2001, 114: 2027-2041.PubMed Stoeber K, Tlsty T, Happerfield L, Thomas G, Romanov S, Bobrow L, Williams E, Williams G: DNA replication, licensing and human cell proliferation. J Cell Sci. 2001, 114: 2027-2041.PubMed
36.
Zurück zum Zitat Sood A, Fletcher M, Gruman L, Coffin J, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor E, Hendrix M: The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 2002, 8: 2924-2932.PubMed Sood A, Fletcher M, Gruman L, Coffin J, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor E, Hendrix M: The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 2002, 8: 2924-2932.PubMed
37.
Zurück zum Zitat Yamaguchi N, Ito E, Azuma S, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Tatsuta K, Inoue K, Semba K, Watanabe S: Fox A1 as a lineage-specific oncogene in luminal type breast cancer. Biochem Biophys Res Commun. 2008, 365: 711-717. 10.1016/j.bbrc.2007.11.064.CrossRefPubMed Yamaguchi N, Ito E, Azuma S, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Tatsuta K, Inoue K, Semba K, Watanabe S: Fox A1 as a lineage-specific oncogene in luminal type breast cancer. Biochem Biophys Res Commun. 2008, 365: 711-717. 10.1016/j.bbrc.2007.11.064.CrossRefPubMed
38.
Zurück zum Zitat Maass N, Teffner M, Rosel F, Pawaresch R, Jonat W, Nagasaki K, Rudolph P: Decline in the expression of the serine proteinase inhibitor maspin is associated with tumor progression in ductal carcinomas of the breast. J Pathol. 2001, 195: 321-326. 10.1002/path.948.CrossRefPubMed Maass N, Teffner M, Rosel F, Pawaresch R, Jonat W, Nagasaki K, Rudolph P: Decline in the expression of the serine proteinase inhibitor maspin is associated with tumor progression in ductal carcinomas of the breast. J Pathol. 2001, 195: 321-326. 10.1002/path.948.CrossRefPubMed
39.
Zurück zum Zitat Reis-Filho J, Milanezi F, Silva P, Schmitt F: Maspin expression in myoepithelial tumors of the breast. Pathol Res Pract. 2001, 197: 817-821. 10.1078/0344-0338-00165.CrossRefPubMed Reis-Filho J, Milanezi F, Silva P, Schmitt F: Maspin expression in myoepithelial tumors of the breast. Pathol Res Pract. 2001, 197: 817-821. 10.1078/0344-0338-00165.CrossRefPubMed
40.
Zurück zum Zitat Takahashi S, Nakamura S, Shinzato K, Domon T, Yamamoto T, Wakita M: Apoptosis and proliferation of myoepithelial cells in atrophic rat submandibular glands. J Histochem Cytochem. 2000, 49: 1557-1564.CrossRef Takahashi S, Nakamura S, Shinzato K, Domon T, Yamamoto T, Wakita M: Apoptosis and proliferation of myoepithelial cells in atrophic rat submandibular glands. J Histochem Cytochem. 2000, 49: 1557-1564.CrossRef
41.
Zurück zum Zitat Wang Z, Herrington B, Schwartz M, Laucirica R: Myoepithelial carcinoma of the parotid gland metastatic to the kidney: case report and review of the literature. Diag Cytopathol. 2010, 38 (suppl 4): 279-282. Wang Z, Herrington B, Schwartz M, Laucirica R: Myoepithelial carcinoma of the parotid gland metastatic to the kidney: case report and review of the literature. Diag Cytopathol. 2010, 38 (suppl 4): 279-282.
42.
Zurück zum Zitat Savera A, Sloman A, Huvos A, Klimstra D: Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 25 patients. Am J Surg Pathol. 2000, 24: 761-774. 10.1097/00000478-200006000-00001.CrossRefPubMed Savera A, Sloman A, Huvos A, Klimstra D: Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 25 patients. Am J Surg Pathol. 2000, 24: 761-774. 10.1097/00000478-200006000-00001.CrossRefPubMed
43.
Zurück zum Zitat Jaehne M, Roeser K, Jaekel T, Schepers J, Albert N, Loning T: Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005, 103: 2526-33. 10.1002/cncr.21116.CrossRefPubMed Jaehne M, Roeser K, Jaekel T, Schepers J, Albert N, Loning T: Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005, 103: 2526-33. 10.1002/cncr.21116.CrossRefPubMed
44.
Zurück zum Zitat Umekita Y, Ohi Y, Sagara Y, Yoshida H: Expression of maspin predicts poor prognosis in breast cancer patients. Int J Cancer. 2002, 100: 452-455. 10.1002/ijc.10500.CrossRefPubMed Umekita Y, Ohi Y, Sagara Y, Yoshida H: Expression of maspin predicts poor prognosis in breast cancer patients. Int J Cancer. 2002, 100: 452-455. 10.1002/ijc.10500.CrossRefPubMed
45.
Zurück zum Zitat Guzinska-Ustymowiczi K, Pryczyiczi A, Kemonai A, Czyzewska J: Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res. 2009, 29: 3049-3052. Guzinska-Ustymowiczi K, Pryczyiczi A, Kemonai A, Czyzewska J: Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res. 2009, 29: 3049-3052.
Metadaten
Titel
Maspin and MCM2 immunoprofiling in salivary gland carcinomas
verfasst von
Shaimaa E Ghazy
Iman M Helmy
Houry M Baghdadi
Publikationsdatum
01.12.2011
Verlag
BioMed Central
Erschienen in
Diagnostic Pathology / Ausgabe 1/2011
Elektronische ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-6-89

Weitere Artikel der Ausgabe 1/2011

Diagnostic Pathology 1/2011 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …